Donanemab and another new drug for Alzheimer’s called Lecanemab have been billed as a huge step forward in research ...

Donanemab, the most effective treatment yet for the disease, has been banned on the health service despite regulators ...

Biogen Inc. (Nasdaq: BIIB) announced upcoming data presentations and programming at the Clinical Trials on Alzheimer’s Disease (CTAD) annual conference, taking place October 29 - November 1, in Madrid ...

Diagnosed with mild cognitive impairment (MCI) in 2018, Mr Almond, from Esher, took part in two 18-month trials for donanemab ...

BioArctic AB's (publ) (Nasdaq Stockholm: BIOA B) founder Lars Lannfelt will be presented with the Lifetime Achievement Award in ...

Health spending watchdog said costs could not justify benefits after treatment slowed cognitive decline by around four to ...

The UK’s National Institute of Health and Care Excellence (NICE) said the drug provided only a small benefit to patients.

The drug is a new treatment for Alzheimer's disease. However ... "Disease-modifying treatments like donanemab and lecanemab offer a new horizon of hope in the fight against dementia. "Today’s ...

A timely diagnosis may become even more pressing if new treatments – such as donanemab and lecanemab ... mild cognitive impairment diagnosed with Alzheimer’s and then potentially have access to new ...

The Dementia Trials Accelerator (DTA) – which will be spearheaded by the UK Dementia Research Institute (UK DRI) and Health ...